SCHEDULE: OrbiMed Advisors Exits RAPT Therapeutics Position

OrbiMed Advisors LLC has filed an amendment to its Schedule 13G, reporting a 0% beneficial ownership stake in RAPT Therapeutics, Inc.

Summary

• OrbiMed Advisors LLC reported that it no longer holds any shares of RAPT Therapeutics, Inc. common stock.
• The filing confirms a 0% ownership stake as of March 31, 2026.
• This amendment serves as a formal notification of the firm's exit from its position in the issuer.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-negative event, as the complete exit of a major institutional investor typically removes a source of stability and may signal a lack of conviction in the company's immediate future.

Positives

• The filing provides clear transparency regarding the complete divestment of the reporting person's position.

Negatives

• The total exit of a significant institutional investor like OrbiMed may be perceived as a lack of confidence in the near-term prospects of the issuer.

Risks

• The loss of a major institutional shareholder can lead to increased stock price volatility.
• Market perception may be negatively impacted by the departure of a prominent healthcare-focused investment firm.

Future Outlook

No forward-looking guidance is provided in this filing as it is a notification of divestment.

Industry Context

StockSavvy.ai notes that institutional exits in the biotech sector are common following clinical trial updates or strategic pivots, often signaling a rebalancing of portfolios by specialized healthcare funds.

Comparison to Industry Standards

• The filing follows standard regulatory requirements for reporting changes in beneficial ownership under the Securities Exchange Act of 1934.
• Divestment filings of this nature are standard practice for institutional investment firms when liquidating positions.

Stakeholder Impact

• Existing shareholders may experience increased volatility due to the institutional exit.
• The company may need to attract new institutional interest to replace the liquidity provided by the former holder.

Next Steps

• No further action required by the reporting person regarding this issuer.

Key Dates

Recommendation

The exit of a major institutional investor warrants a hold recommendation until the company provides further clarity on its strategic direction and clinical pipeline progress to justify new institutional entry.

Keywords

RAPT Therapeutics, OrbiMed Advisors, Schedule 13G, Divestment, Institutional Ownership, Biotech